Category: Sanofi-AventisSyndicate content

TAVI: Direct Flow taps ex-CoreValve chief Lemaitre | Personnel Moves

May 7, 2015 by Brad Perriello

Direct Flow Medical taps the former chief at CoreValve, Daniel Lemaitre, to be its new CEO and names pharma finance vet David Boyle as CFO.

Direct Flow taps ex-CoreValve chief Lemaitre | Personnel Moves

BAX drops FloSeal case against J&J | Medtech legal news for the week of April 13, 2015

April 13, 2015 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Baxter drops FloSeal case against J&J; Feds: We got $119m in fraud penalties from medtech companies last year; Insurer, DJO Global settle pain pump suit

Baxter drops FloSeal case against J&J

April 6, 2015 by Brad Perriello

YYmeta

Feds: We got $119m in fraud penalties from medtech companies last year

April 8, 2015 by Brad Perriello

The U.S. Health & Human Services Dept. and the Justice Dept. say they collected some $119 million in healthcare fraud penalties from medical device companies during fiscal 2014.

Feds: We got $119m in fraud penalties from medtech companies last year

Report: Smith & Nephew CEO Bohoun to stay put

December 1, 2014 by Brad Perriello

Smith & Nephew CEO Olivier Bohuon reportedly tells employees that he's not in the running for the top job at French drug maker Sanofi.

Report: Smith & Nephew CEO Bohoun to stay put

Smith & Nephew's Bohuon seen as strong candidate for top Sanofi job

November 4, 2014 by MassDevice

Smith & Nephew CEO Olivier Bohuon is said to be a leading candidate for the top job at French drugmaker Sanofi, which axed its CEO last week without a replacement.

YYmeta

Diabetes: Medtronic and Sanofi ally on new drug-device combinations

June 16, 2014 by Arezu Sarvestani

Medtronic and Sanofi embark on a global alliance to combine human and financial resources in the interest of new products and services for patients with diabetes.

Diabetes: Medtronic and Sanofi ally for drug-device combinations

Whistleblower lawsuit costs Genzyme $22M

January 3, 2014 by Arezu Sarvestani

Sanofi subsidiary Genzyme agrees to pay $22.3 million to settle accusations that its sales rep encouraged off-label use of the Seprafilm surgical product.

Whistleblower lawsuit costs Genzyme $22M

Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product.